skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Monoamine depletion by reuptake inhibitors

Original Research

(1833) Views  (916) Full article downloads

Authors: Hinz M, Stein A, Uncini T

Published Date October 2011 Volume 2011:3 Pages 69 - 77
DOI: http://dx.doi.org/10.2147/DHPS.S24798

Marty Hinz1, Alvin Stein2, Thomas Uncini3
1Clinical Research, NeuroResearch Clinics Inc, Cape Coral, FL; 2Stein Orthopedic Associates, Plantation, FL; 3DBS Labs Inc, Duluth, MN, USA

Background: Disagreement exists regarding the etiology of cessation of the observed clinical results with administration of reuptake inhibitors. Traditionally, when drug effects wane, it is known as tachyphylaxis. With reuptake inhibitors, the placebo effect is significantly greater than the drug effect in the treatment of depression and attention deficit hyperactivity disorder, leading some to assert that waning of drug effects is placebo relapse, not tachyphylaxis.
Methods: Two groups were retrospectively evaluated. Group 1 was composed of subjects with depression and Group 2 was composed of bariatric subjects treated with reuptake inhibitors for appetite suppression.
Results: In Group 1, 200 subjects with depression were treated with citalopram 20 mg per day. A total of 46.5% (n = 93) achieved relief of symptoms (Hamilton-D rating score ≤ 7), of whom 37 (39.8%) of whom experienced recurrence of depression symptoms, at which point an amino acid precursor formula was started. Within 1–5 days, 97.3% (n = 36) experienced relief of depression symptoms. In Group 2, 220 subjects were treated with phentermine 30 mg in the morning and citalopram 20 mg at 4 pm. In this group, 90.0% (n = 198) achieved adequate appetite suppression. The appetite suppression ceased in all 198 subjects within 4–48 days. Administration of an amino acid precursor formula restored appetite suppression in 98.5% (n = 195) of subjects within 1–5 days.
Conclusion: Reuptake inhibitors do not increase the total number of monoamine molecules in the central nervous system. Their mechanism of action facilitates redistribution of monoamines from one place to another. In the process, conditions are induced that facilitate depletion of monoamines. The "reuptake inhibitor monoamine depletion theory" of this paper offers a novel and unified explanation for the waning of response seen after a reuptake inhibitor is started, independent of a drug or placebo etiology.

Keywords: reuptake inhibitor, depletion, tachyphylaxis, relapse, serotonin, dopamine





 

Other articles by Dr Marty Hinz

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Amino acid management of Parkinson’s disease: a case study
Amino acid-responsive Crohn's disease: a case study
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Neurotransmitter testing of the urine: a comprehensive analysis
Relative nutritional deficiencies associated with centrally acting monoamines
The discrediting of the monoamine hypothesis
The dual-gate lumen model of renal monoamine transport
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”


Readers of this article also read:

Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Neurotransmitter testing of the urine: a comprehensive analysis
A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Amino acid-responsive Crohn's disease: a case study
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Amino acid management of Parkinson’s disease: a case study
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
APRESS: apical regulatory super system, serotonin, and dopamine interaction
The discrediting of the monoamine hypothesis
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio